Surge In Covid JN 1 Variant Cases Sparks Panic; Monitor Symptoms.

(CTN News) – In light of the recent surge in COVID-19 cases caused by the newly identified JN.1 variant, a former WHO scientist has issued cautionary advice urging nationwide vigilance.

Several states have promptly implemented preemptive measures to address the increase in infections, with health advisories stressing the importance of wearing masks and conducting extensive testing.

Over the past 24 hours, the country has recorded a total of 358 new Covid cases, with a staggering 300 cases reported in Kerala alone. Tragically, six deaths related to Covid were also documented during this period.

According to the latest data from the health ministry dashboard, India currently has 2,669 active Covid cases. On December 20, the country witnessed the highest daily figure since May, with 614 cases reported.

Despite being classified as a “variant of interest” by the World Health Organisation, the JN.1 subvariant of Covid has been clarified as not currently posing a significant risk.

Please review the symptoms.

The Covid subvariant JN.1 variant is characterized by symptoms such as fever, runny nose, sore throat, headaches, occasional gastrointestinal issues, severe fatigue, exhaustion, and muscle weakness.

It is crucial to note that medical experts strongly recommend getting a Covid test if these symptoms persist for more than two days.

In light of the increasing number of infections, former WHO chief scientist Soumya Swaminathan has cautioned against underestimating Covid as a common cold.

She emphasized not only the severity of cases but also the potential long-term effects of the virus. While there is hope that JN.1 might exhibit mild behavior similar to Omicron, Swaminathan also warned about the possibility of new variants becoming more transmissible over time.

Swaminathan specifically highlighted the variant’s ability to evade existing antibody responses, which increases the risk of recurrent waves of infections among individuals who were previously infected.

Given this situation, it is crucial to maintain vigilance and take proactive measures to mitigate the impact of emerging variants on public health.

SEE ALSO:

Sanofi Ends Lung Cancer ADC Development After Failed Phase III Trial.

Dispelling Common Eyelash Extensions Myths!